A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Molecular Imaging
  • Positron-Emission Tomography
  • Prostatic Neoplasms
  • Radiopharmaceuticals

abstract

  • (89)Zr-J591 imaging demonstrated superior targeting of bone lesions relative to CIMs. Targeting soft-tissue lesions was less optimal, although (89)Zr-J591 had similar accuracy as individual CIMs. This study will provide benchmark data for comparing performance of proposed prostate-specific membrane antigen (PSMA) targeting agents for prostate cancer. Clin Cancer Res; 21(23); 5277-85. ©2015 AACR.

publication date

  • December 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4668231

Digital Object Identifier (DOI)

  • 10.1158/1078-0432.CCR-15-0552

PubMed ID

  • 26175541

Additional Document Info

start page

  • 5277

end page

  • 85

volume

  • 21

number

  • 23